(PDF) Budget Impact Analysis of Biphasic Insulin Aspart in

Budget Impact Analysis of Biphasic Insulin Aspart in the Treatment of Type 2 Diabetes Mellitus in Malaysia: A Public Payer Perspective

Value in Health - United Kingdom

doi 10.1016/j.jval.2014.08.151

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

November 1, 2014

Authors

Publisher

Elsevier BV

Related search

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Turkish Journal of Endocrinology and Metabolism

Internal Medicine

English

Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial

European Journal of Endocrinology

English

15 Years of Experience With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Drugs in R and D

English

Initiation of Biphasic Insulin Aspart in a Patient Failing Basal Insulin Treatment

European Endocrinology

Autonomic Systems

English

Budget Impact Analysis of Adding Dapaglifozin to the Therapy of Diabetes Mellitus Type 2 in Bulgaria

Value in Health

Occupational Health

English

Pdb38 - Budget Impact Analysis of Benaglutide Injection in the Treatment of Type 2 Diabetes in China

Value in Health

Occupational Health

English

Budget Impact Analysis of Utilizing Canagliflozin (CANA) for the Treatment of Type 2 Diabetes Mellitus (T2DM) in an United States Health Plan

Value in Health

Occupational Health

English

Pdb37 - Budget Impact Analysis of the Adult Type 1 Diabetes Mellitus National Clinical Guideline in Ireland

Value in Health

Occupational Health

English

Budget Impact Analysis of Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer From a u.s. Payer Perspective

Value in Health

Occupational Health

English